Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, announced that CEO Troy Wilson will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, announced that CEO Troy Wilson will participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET. The presentation will be available for 90 days in the Investors section of Kura's website. The company is advancing several drug candidates, including Ziftomenib for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer.
Details
News Market Reaction – KURA
The recorded move for KURA in the trading session of this news was +8.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be available to view on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 12, 2022.
The pre-recorded presentation will remain accessible for 90 days in the Investors section of Kura’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.
Contacts
Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.